Annual accounts receivable:
$27.12M+$5.94M(+28.03%)Summary
- As of today (July 1, 2025), TVTX annual accounts receivable is $27.12 million, with the most recent change of +$5.94 million (+28.03%) on December 31, 2024.
- During the last 3 years, TVTX annual accounts receivable has risen by +$11.20 million (+70.39%).
- TVTX annual accounts receivable is now at all-time high.
Performance
TVTX Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$34.38M+$7.26M(+26.79%)Summary
- As of today (July 1, 2025), TVTX quarterly accounts receivable is $34.38 million, with the most recent change of +$7.26 million (+26.79%) on March 31, 2025.
- Over the past year, TVTX quarterly accounts receivable has increased by +$11.65 million (+51.25%).
- TVTX quarterly accounts receivable is now at all-time high.
Performance
TVTX Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
TVTX Accounts receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +28.0% | +51.3% |
| 3 y3 years | +70.4% | +134.3% |
| 5 y5 years | +50.2% | +90.1% |
TVTX Accounts receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +70.4% | at high | +171.4% |
| 5 y | 5-year | at high | +70.4% | at high | +189.9% |
| alltime | all time | at high | +240.7% | at high | >+9999.0% |
TVTX Accounts receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $34.38M(+26.8%) |
| Dec 2024 | $27.12M(+28.0%) | $27.12M(+7.7%) |
| Sep 2024 | - | $25.17M(+2.9%) |
| Jun 2024 | - | $24.47M(+7.6%) |
| Mar 2024 | - | $22.73M(+7.3%) |
| Dec 2023 | $21.18M(+27.2%) | $21.18M(+45.4%) |
| Sep 2023 | - | $14.57M(-28.6%) |
| Jun 2023 | - | $20.40M(-5.3%) |
| Mar 2023 | - | $21.54M(+29.4%) |
| Dec 2022 | $16.65M(+4.6%) | $16.65M(+31.4%) |
| Sep 2022 | - | $12.67M(-24.1%) |
| Jun 2022 | - | $16.69M(+13.7%) |
| Mar 2022 | - | $14.68M(-7.8%) |
| Dec 2021 | $15.91M(-0.1%) | $15.91M(+19.0%) |
| Sep 2021 | - | $13.37M(+12.7%) |
| Jun 2021 | - | $11.86M(-9.2%) |
| Mar 2021 | - | $13.07M(-18.0%) |
| Dec 2020 | $15.93M(-11.8%) | $15.93M(+6.0%) |
| Sep 2020 | - | $15.03M(+6.7%) |
| Jun 2020 | - | $14.08M(-22.2%) |
| Mar 2020 | - | $18.09M(+0.2%) |
| Dec 2019 | $18.05M | $18.05M(+7.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2019 | - | $16.78M(+8.6%) |
| Jun 2019 | - | $15.45M(+21.5%) |
| Mar 2019 | - | $12.71M(+0.4%) |
| Dec 2018 | $12.66M(-8.7%) | $12.66M(-5.9%) |
| Sep 2018 | - | $13.45M(+9.1%) |
| Jun 2018 | - | $12.32M(-5.1%) |
| Mar 2018 | - | $12.98M(-6.4%) |
| Dec 2017 | $13.87M(-25.1%) | $13.87M(-4.6%) |
| Sep 2017 | - | $14.54M(+9.2%) |
| Jun 2017 | - | $13.32M(-13.7%) |
| Mar 2017 | - | $15.43M(-16.7%) |
| Dec 2016 | $18.51M(+48.6%) | $18.51M(+23.8%) |
| Sep 2016 | - | $14.96M(-9.7%) |
| Jun 2016 | - | $16.57M(+23.6%) |
| Mar 2016 | - | $13.40M(+7.6%) |
| Dec 2015 | $12.46M(+56.5%) | $12.46M(-7.7%) |
| Sep 2015 | - | $13.50M(+17.7%) |
| Jun 2015 | - | $11.47M(+40.5%) |
| Mar 2015 | - | $8.16M(+2.5%) |
| Dec 2014 | $7.96M | $7.96M(+70.2%) |
| Sep 2014 | - | $4.68M(+192.1%) |
| Jun 2014 | - | $1.60M(+5458.3%) |
| Mar 2014 | - | $28.80K |
FAQ
- What is Travere Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Travere Therapeutics?
- What is Travere Therapeutics annual accounts receivable year-on-year change?
- What is Travere Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Travere Therapeutics?
- What is Travere Therapeutics quarterly accounts receivable year-on-year change?
What is Travere Therapeutics annual accounts receivable?
The current annual accounts receivable of TVTX is $27.12M
What is the all time high annual accounts receivable for Travere Therapeutics?
Travere Therapeutics all-time high annual accounts receivable is $27.12M
What is Travere Therapeutics annual accounts receivable year-on-year change?
Over the past year, TVTX annual accounts receivable has changed by +$5.94M (+28.03%)
What is Travere Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of TVTX is $34.38M
What is the all time high quarterly accounts receivable for Travere Therapeutics?
Travere Therapeutics all-time high quarterly accounts receivable is $34.38M
What is Travere Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, TVTX quarterly accounts receivable has changed by +$11.65M (+51.25%)